The Yu Lab at Cornell recently published a study of SARS-CoV-2-viral and human proteins that interact with each other, which open doors for identifying potential treatments.
A highly innovative method using the latest technology opens myriad new avenues for research, for understanding the biology behind COVID-19, and for identifying new treatments that target protein binding sites.
A Cleveland Clinic-led research team used artificial intelligence to map out hundreds of ways that the virus that causes COVID-19 interacts with infected cells.
A computational tool will greatly benefit our understanding of the SARS-COV-2 virus and the development of drugs that block sites where the virus binds with human proteins.
Seed grants and symposia based on themes from the Office of Academic Integration have bridged researchers from the Ithaca and New York campuses and have brought a high return on investment to Cornell.